Prelude Therapeutics Inc (PRLD NASDAQ) stock market data APIs
$1.6436
0.02(1.2%)
as of December 11, 2025
Try our APIs with
free plan!
Prelude Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prev. Close
1.6436
Open
1.6587
High
1.7005
Low
1.626
52 wk Range
0.6101-4.22
Market Cap
102 M
Shares Outstanding
50 015 K
Revenue
10 500 K
EPS
-0.26
Beta
1.056
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Prelude Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Prelude Therapeutics Inc data using free add-ons & libraries
Get Prelude Therapeutics Inc Fundamental Data
Prelude Therapeutics Inc Fundamental data includes:
- Net Revenue: 10 500 K
- EBITDA: -119 267 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-18
- EPS/Forecast: -0.3697
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Prelude Therapeutics Inc News
New
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on trac...
Penny Stocks To Consider In December 2025
As December 2025 begins, U.S. stock indexes have slipped, with major tech and cryptocurrency-tied shares experiencing declines amid a broader risk-off sentiment in the market. Despite this cautious at...
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therape...
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
Last Friday, the three most widely followed benchmark indexes closed a losing week. The tech-heavy Nasdaq, the S&P 500 and the Dow Jones slid 2.7%, 2% and 1.9%, respectively. Nasdaq witnessed its thir...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
